RxDoctor Payments Data

Xinke Chen, MD

Hospitalist · Corona, CANPI 1780634857

Payments from drug & device makers

$1,602in general payments, 2019–2025

Across 117 payments — averaging $13.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$899
  • Johnson & Johnson$146
  • Urgo Medical North America, LLC$99
  • Biotissue Holdings Inc.$78
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$59
  • Misonix Inc$48
  • plus $274 from 11 others

What the payments were for

  • Food & beverage$1,602100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,602 in reported general payments places this provider in the 90th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$334,161
Medicare patients
192
Services billed
3,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tolvaptan13$108,822
EliquisApixaban205$91,332
OzempicSemaglutide26$23,469
JanuviaSitagliptin Phosphate26$17,712
ProcritEpoetin Alfa19$12,875
Budesonide51$9,613
OxycontinOxycodone Hcl11$8,726
Fluphenazine Hcl17$8,480
LinzessLinaclotide16$8,449
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,726
TrintellixVortioxetine Hydrobromide25$6,161
BrilintaTicagrelor14$6,093
Atorvastatin Calcium422$5,859
Cefepime Hcl26$4,853
Scopolamine41$4,803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$26$23,46926 claims
Johnson & JohnsonProcrit$146$12,87519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →